<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="381">
  <stage>Registered</stage>
  <submitdate>2/09/2005</submitdate>
  <approvaldate>12/01/2007</approvaldate>
  <actrnumber>ACTRN12607000043437</actrnumber>
  <trial_identification>
    <studytitle>Weekly Carboplatin and Taxol with concurrent radiotherapy for locally advanced non small cell lung : Predictive factors for completion of treatment.</studytitle>
    <scientifictitle>Weekly Carboplatin and Taxol with concurrent radiotherapy for locally advanced non small cell lung cancer:Predictive factors for completion of treatment.</scientifictitle>
    <utrn />
    <trialacronym>CARBOTAX</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Non Small Cell Lung Cancer (NSCLC)</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>6 cycles of weekly carboplatin and paclitaxel , concurrent radiotherapy and either induction or consolidation carboplatin and paclitaxel (2 x 3 weekly cycles). This is a complex protocol with dosages changing according to whether the patient is receiving concurrent treatment it is not practical to give the doses of every drug at every time. The mode of administration for each drug is intravenous. There is no control group.</interventions>
    <comparator>There is no control group.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of patients completing treatment</outcome>
      <timepoint>Measured at the end of protocol, which is at the end of the induction/consolidation and concurrent treatment the exact length this will be will depend upon the gap between the treatments and associated treatment delays. The date of assessment for the primary outcome is not fixed but the "timepoint" will depnd upon treatment duration for each patient</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Median overall and progression free survival.</outcome>
      <timepoint>Measured at 3 monthly follow ups until death.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria> Stage IIIA/B histologically proven NSCLC. ECOG Performance Status 0 or1. Weight loss &lt; 10% compared to original (pre-diagnosis) weight.  FeV1 (Forced Expiratory volume 1 second) &gt; 1.0L. Adequate hematological and biochemical reserve.  </inclusivecriteria>
    <inclusiveminage>17</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Glomerular Filtration Rate (GFR)  &lt; 50ml/min (Cockroft-Gault formula). Prior chemotherapy or irradiation. Prior diagnosis of invasive cancer within the last 2 years.  Symptomatic sensory or motor neuropathy.  Contraindications to steroids.  Pregnant or breastfeeding mothers.  Intercurrent medical illnesses precluding combined modality therapy (except with clinician's authorisation).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Other</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/01/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>45</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>South Eastern Illawarra Area Health service</primarysponsorname>
    <primarysponsoraddress>SESIAHS
c/o St George Hospital Gray St Kogarah 2217</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Bristol Myers Squibb</fundingname>
      <fundingaddress>556 Princes Highway
Noble Park North 3174 
PO Box 39 
Noble Park North 3174</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial aims to determine the effiacy and toxicity of a standard treatment approach to locally advanced NSCLC in NSW and to examine potential predictors of treatment tolerability.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>st george</ethicname>
      <ethicaddress />
      <ethicapprovaldate>10/10/2003</ethicapprovaldate>
      <hrec>03-152</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bankstown</ethicname>
      <ethicaddress />
      <ethicapprovaldate>4/02/2004</ethicapprovaldate>
      <hrec>03/153</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Wollongong</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/08/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead</ethicname>
      <ethicaddress />
      <ethicapprovaldate>3/11/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>POW</ethicname>
      <ethicaddress />
      <ethicapprovaldate>4/05/2005</ethicapprovaldate>
      <hrec>03/241</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>RNSH</ethicname>
      <ethicaddress />
      <ethicapprovaldate>13/09/2004</ethicapprovaldate>
      <hrec>0403-073M</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Matthew Links</name>
      <address>Clinical Trials Unit
St George Hospital
Kogarah NSW 2217</address>
      <phone>+61 2 93501935</phone>
      <fax>+61 2 93502960</fax>
      <email>Matthew.Links@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Antoinette Fontela</name>
      <address>Clinical Trials Unit
St George Hospital
Kogarah NSW 2217</address>
      <phone>+61 2 93501935</phone>
      <fax>+61 2 93502960</fax>
      <email>Antoinette.Fontela@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>